Anebulo Pharmaceuticals Inc

NASDAQ ANEB
$2.38 -0.0100 -0.42%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 13.75 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
53.41M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
40.13M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
41.09M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
41.67 %

Upcoming events Anebulo Pharmaceuticals Inc

All events
No upcoming events scheduled

Stock chart Anebulo Pharmaceuticals Inc

Stock analysis Anebulo Pharmaceuticals Inc

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-6.95 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
11.38 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-6.11 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
2.02 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-57.12 -50.00

Price change Anebulo Pharmaceuticals Inc per year

0.94$ 3.08$
Min Max

Summary analysis Anebulo Pharmaceuticals Inc

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Anebulo Pharmaceuticals Inc

Revenue and net income Anebulo Pharmaceuticals Inc

All parameters

About company Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.
Address:
1017 Ranch Road 620 South, Lakeway, TX, United States, 78734
Company name: Anebulo Pharmaceuticals Inc
Issuer ticker: ANEB
ISIN: US0345691036
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2021-05-07
Sector: Healthcare
Industry: Biotechnology
Site: https://www.anebulo.com